Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

• Status: Active, not recruiting
• Trial end date: 2026-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Louisville
• Treatments: Nivolumab

Criteria

Inclusion Criteria:

• ≥ 18 years if age

• Diagnosed with stage III pancreatic cancer

• Tumor is measurable

• Glomerular Filtration Rate > 60 m/L/min/1.73 m(2)

• Willing and able to comply with the protocol requirements

• Able to comprehend and have signed the informed consent to participate

Exclusion Criteria:

• Participating in another clinical trial for the treatment of cancer at time of screening

• Are pregnant or currently breast feeding

• Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure

• Have non-removable implants with metal parts within 1 cm of the target lesion

• Had a myocardial infarction within 3 months prior to enrollment